WO2006059397A1 - 抗ストレス性食品 - Google Patents
抗ストレス性食品 Download PDFInfo
- Publication number
- WO2006059397A1 WO2006059397A1 PCT/JP2004/018344 JP2004018344W WO2006059397A1 WO 2006059397 A1 WO2006059397 A1 WO 2006059397A1 JP 2004018344 W JP2004018344 W JP 2004018344W WO 2006059397 A1 WO2006059397 A1 WO 2006059397A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pork
- peptide
- stress
- anserine
- carnosine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
Definitions
- the present invention relates to an anti-stress food. More specifically, the present invention relates to an anti-stress food that can prevent or ameliorate the stress experienced by humans or animals. Background art
- stress which includes environmental factors such as noise and earthquakes, social factors such as economic crises and political changes, anxiety, and irritation.
- factors such as mental factors such as conflicts in human relations and physical factors such as fatigue and illness.
- mental stress is also manifested as physical stress. For example, poor digestion and ulcers occur in the digestive tract, and the immune system has a wide range of allergic symptoms such as herpes zoster, cattopy, loss of appetite, reduced motivation for daily activities, and depression.
- stress reduces the function of various organs, decreases insulin secretion and decreases the metabolic capacity of sugar, etc., delays the recovery time of fatigue, decreases endurance, etc. It has been known. It has been reported that a decrease in insulin secretion can be an indicator of stress (Biol. Pharm. Bull. 21 (2), 113-116, 1998).
- anti-stress foods examples include an anti-stress composition containing an imidazole-based compound (Japanese Patent Laid-Open No. 9-206606) and an anti-stress agent containing a sweet potato-derived component (Japanese Patent Laid-Open No. 2000). 1-3 3 5 5 0 5)) is known, but the effect is not always sufficient, and the development of anti-stress foods that have excellent effects and can cope with a wide range of stress causes It was anxious. As a result of various investigations, the present inventors have found that, when carnosine and / or anserine and pork peptide, which is an enzyme degradation product of pork, are used in combination, the food has an excellent antistress action due to its synergistic effect.
- the present invention was made on the basis of such findings, and it was found that carnosine and / or anserine and pork enzyme can be obtained by further adding glycerophospholipid to the food having a very excellent anti-stress action due to its synergistic effect.
- the present invention provides an anti-stress food containing a pork peptide that is a degradation product, and preferably further containing glycerophospholipid.
- Carnosine and anserine are known to have an anti-stress action (Japanese Patent Laid-Open No. 9-260660).
- the pork peptide is an enzyme degradation product of pork and is known to have a cholesterol lowering effect and a liver function improving function (Patent No. 2 6 1 8 2 98).
- glycerophospholipid is a phospholipid widely distributed in living bodies such as the brain and nervous system.
- phosphatidylserine is a phospholipid contained in brain cells, particularly nerve cell membranes, and promotes glucose uptake. It has functions of promoting neurite progression and enhancing hormones in the brain, and has the effect of increasing learning ability and memory ability (Japanese Patent Application Laid-Open No. 7-17855). It has not been known that carnosine and / or pork peptides, which are enzyme breakdown products of anserine and pork, and darisserophospholipid components synergistically act on stress. Disclosure of the invention
- the gist of the present invention is an anti-stress food that contains carnosine and / or a peptide that is an enzymatic degradation product of anserine and pork, and may further contain glyce mouth phospholipid.
- Carnosine and / or anserine may be combined as a chicken extract (or its powder).
- Carnosine and / or anserine and pork peptide, which is an enzymatic degradation product of pork include carnosine and / or anserine: pork peptide, which is an enzymatic degradation product of pork, 1: 1 to 10 (weight ratio) and
- the mixing ratio of carnosine and / or anserine and pork, which is an enzyme degradation product of pork and glycerophospholipid is set to carnosine and / or anserine: pig. It is preferable to adjust pork peptide: glyce mouth phospholipid, which is an enzyme degradation product of meat, to 1: 1 to 10: 1 to 5 (weight ratio).
- the present invention is an anti-stress food containing carnosine and Z or anserine and pork peptide which is an enzyme degradation product of pork, preferably further containing glyceport phospholipid.
- Carnosine and anserine which are one of the active ingredients of the present invention, are already known substances.
- carnosine and anserine may be used alone or in combination.
- Carnosine and anserine may be in free form, and are acid addition salts (eg, hydrochloride, acetate, kenate, etc.), alkali addition salts (eg, sodium salt, potassium salt, ammonium salt, etc.). May be.
- carnosine and anserine chemically synthesized products or fermentation products can be used, but it is preferable to use an extract from a natural product in terms of cost.
- carnosine and anserine are contained in a large amount in chicken, fish, etc., they can be obtained by using waste materials when manufacturing processed foods using these.
- carnosine and anserine derived from chicken which can be obtained from chicken according to the method described in Japanese Patent Application Laid-Open No. 2000-057.
- An example of this is explained in detail: chicken meat is shredded, warm water is added, acid or alkali is added, and then the solution obtained by extraction in warm water is desalted with a column or the like and treated with protease. Can be obtained.
- Any acid can be used as long as it can be added to food.
- Examples include hydrochloric acid, citrate, acetic acid, and ascorbic acid. used.
- examples of the alkalinity include sodium hydroxide, lithium hydroxide, triethanolamine and the like.
- the amount of acid or alkali used for chicken is 0.01% by weight or more, usually 0.1 to 2.0% by weight.
- the extraction conditions are not particularly limited, but are usually performed by treating at 90 ° C for about 4 hours.
- the obtained extract can be desalted according to a conventional method.
- any enzyme capable of degrading proteins can be used. Examples include pine, trypsin, and pepsin, and papine is preferably used. Two or more types of such proteases may be used in combination.
- the amount of the protease used for the chicken extract is 0.005% by weight or more, usually about 0.01 to 10% by weight.
- the enzyme treatment conditions are not particularly limited, but it is usually performed by treating at 50 ° C for about 1 hour. After enzyme treatment, heat to inactivate the enzyme, then neutralize, purify with a column, etc., desalinate, dry by various methods, for example, hot air drying, spray drying,? It can be dried by Toyu drying, etc., and chicken processed powder (hereinafter referred to as chicken extract powder) can be prepared.
- the chicken extract powder thus obtained contains carnosine and anserine, preferably 3-20% carnosine, 5-30% anserine, more preferably 3-20% carnosine and 10-30% anserine. And a peptide mixture.
- pork peptide which is an enzyme degradation product of pork, which is one of the active ingredients of the present invention, is a peptide obtained by enzymatic degradation of pork. It is disclosed in the specification of No. 2 98 and can be prepared according to the method described in the specification.
- a slurry obtained by chopping pork, defatting and adding water can be obtained by treating with protease.
- any enzyme can be used as long as it is capable of degrading proteins. Examples thereof include haha-hain, trypsin, pepsin, and the like, preferably papain used. Two or more types of proteases may be used in combination.
- the amount of protease used for pork is 0.005% by weight or more, usually about 0.01 to 1% by weight.
- the enzyme treatment conditions are not particularly limited, but are usually performed by treating at about 50 ° C. for about 24 hours.
- the pork peptides thus obtained are generally peptides having a molecular weight of about 3000 and rich in hydrophobic amino acids.
- glyceport phospholipid which is one of the active ingredients of the present invention, is a known substance, and those already on the market can be used.
- examples of such glyceport phospholipids include phosphatidinoesters (for example, phosphatidylserine, phosphatidyl). Choline, phosphatidylethanolamine, etc.), phosphatidic acids (eg, cardiolipin), acetal phospholipids (eg, phosphatidylethanolamine), and lysophospholipids (eg, lysolecithin).
- phosphatidyl esters are used, more preferably phosphatidylserine.
- the above-mentioned glyceport phospholipid may be in a free form, and may be an acid addition salt (for example, hydrochloride, acetate, kenate, etc.), an alkali addition salt (for example, sodium salt, potassium salt, ammonium salt). Etc.)
- an acid addition salt for example, hydrochloride, acetate, kenate, etc.
- an alkali addition salt for example, sodium salt, potassium salt, ammonium salt.
- the compounding ratio of carnosine and no or anserine and pork peptide is not particularly limited as long as a synergistic effect is obtained, but carnosine and Z or anserine: pork peptide is 1: 1 to: I 0. (Weight ratio, the same applies hereinafter), preferably adjusted to 1: 3 to 8, more preferably about 1: 5 to 7.
- dariceroline fat preferably phosphatidylserine
- the blending ratio of lipid is adjusted to about 1: 1 to I0: 1 to 5, preferably 1: 2 to 7: 1.5 to 4, more preferably about 1: 3 to 5: 2 to 3.
- the intake of the anti-stress food of the present invention can be adjusted as appropriate according to the severity of symptoms, stress factors, body weight, age, etc., but usually 10 to 50 O mg / kg body weight It is preferably 30 to 20 O mg / kg body weight, more preferably 50 to 15 O mg / kg body weight, and it may be taken once a day or divided into several times.
- the antistress food of the present invention is ingested by humans as it is in various forms such as solids and foods.
- the above three components are mixed with components necessary for formulation such as appropriate physiologically acceptable additives (for example, carriers, excipients, diluents, etc.) as necessary. It can be obtained by preparing it in an appropriate dosage form, and examples of the form include tablets, powders, condylar granules, and force capsules.
- appropriate physiologically acceptable additives for example, carriers, excipients, diluents, etc.
- Examples of the food and drink include beverages (for example, drinks, milk beverages, coffee beverages, tea beverages, green tea beverages, juices, etc.), confectionery (for example, biscuits, cookies)
- beverages for example, drinks, milk beverages, coffee beverages, tea beverages, green tea beverages, juices, etc.
- confectionery for example, biscuits, cookies
- Such foods and drinks can be prepared according to conventional methods, except that the active ingredient is added in an appropriate process in the preparation stage.
- conventional additives may be added to such foods and drinks.
- examples of such additives include vitamins, minerals, hormones, physiologically active substances, and sweeteners.
- anti-stress food of the present invention can be added with ingredients commonly used in this field, if necessary.
- the anti-stress food of the present invention is effective in preventing and improving mental or physical stress experienced by humans based on various factors. Further, the anti-stress food of the present invention is effective not only for human but also for prevention / amelioration of stress of various animals.
- animals mean mammals other than humans for convenience, and such mammals include livestock such as cattle, pigs, sheep, and horses, for example, companion animals such as dogs and cats. It can be illustrated.
- the anti-stress food of the present invention contains carnosine and / or anserine and pork peptide, more preferably glyceport phospholipid as an active ingredient. Due to the synergistic effect of these ingredients, Prevention of mental or physical stress based on the factors of: 'Improvement of glucose tolerance, anti-gastric ulcer action, fatigue recovery action, improvement of exercise ability sustainability, liver function ( For example, serum
- Carnosine and anserine-containing chicken extract powder was produced by the following process. 4 018344 Cut chicken with meat grinder, add 1.5 times the weight of warm water to the weight of meat, then add 0.2% of citrate to the weight of meat to make PH 5.5. After extraction at 90 ° C. for 4 hours, an insoluble material of 100 mesh or more was removed by filtration to obtain an extract. To this, papain was added in an amount of 0.06% to the extract, reacted at 50 for 1 hour, and then heated at 90 ° C for 15 minutes to inactivate the enzyme. Then, it was freeze-dried and crushed to obtain a dry powder of 50 mesh or less. The chicken extract powder thus obtained was used for the following tests.
- the chicken extract powder contained 5% carnosine and 10% anserine.
- Pork lean meat was minced with a meat grinder, degreased, freeze-dried, and water was added to prepare a pork lean slurry (protein concentration about 5%).
- papain 50 ° C, P H7. 0 at reacted for 24 hours, followed by heating 1 hour at 90 ° C, to inactivate the enzyme. Filter the supernatant of the papain hydrolyzate and collect fractions with a molecular weight of 10,000 or less by ultrafiltration. It was dried by Toyu and crushed to obtain a dry powder of 50 mesh or less.
- the pork peptide thus obtained was used in the following tests.
- mice Six week old female ICR mice were pre-bred for one week, and then animals with no abnormalities in general condition and weight gain were used in the experiment. At the same time, for the group that was orally administered an aqueous solution of a mixture of the above chicken extract powder 30 mg / ml + pork peptide 20 mg / ml + phosphatidylserine 10 mg / ml once a day at a dose of 10 ml / kg, Mice were placed in an open 50 ml polystyrene tube and subjected to restraint stress for 16 days (6: 0 OPM to 10: 0 OAM) for 2 days under fasting fasting.
- Example 2 In Example 1, the same treatment was performed except that an aqueous solution of a mixture of chicken extract powder 30 mg / ml + pork peptide 20 mg / ml was administered as the aqueous solution.
- Example 1 the same treatment was performed except that an aqueous solution of a mixture of chicken extract powder 30 mg / ml + phosphatidylserine 10 mg / ml was administered as the aqueous solution.
- Example 1 the same treatment was conducted except that an aqueous solution of a mixture of pork peptide 20 mg / ml + phosphatidylserine 10 mg / ml was administered as an aqueous solution.
- Example 1 the same treatment was performed except that an aqueous solution of chicken extract powder 30 mg / ml was administered as the aqueous solution.
- Example 1 the same treatment was performed except that an aqueous solution of 20 mg / ral pork peptide was administered as the aqueous solution.
- Example 1 the same treatment was performed except that an aqueous solution of phosphatidylserine 10 mg / ml was administered as the aqueous solution.
- Example 1 the same treatment was performed except that only water was administered as an aqueous solution.
- the results of the above test are shown in Table 1 below.
- the amount of insulin secretion in Comparative Example 6 decreased to 20.0% of the control group due to restraint stress. Furthermore, in the group to which only one of chicken extract powder, pork peptide, and phosphatidylserine was administered, they were only 32%, 23%, and 23%, respectively.
- Example 3 In Example 1, the same treatment was performed except that an aqueous solution of a mixture of chicken extract powder 25 mg / ml + pork peptide 25 mg / ml was administered as the aqueous solution.
- Example 1 the same treatment was performed except that an aqueous solution of 50 mg / ml chicken extract powder was administered as the aqueous solution.
- Example 1 the same treatment was performed except that an aqueous solution of 50 mg / inl pork peptide was administered as the aqueous solution.
- mice The test aqueous solution was administered to mice, and the effect on endurance improvement was investigated.
- Five-week-old male ddY mice purchased from Nippon SLC Co., Ltd.
- CE-2 Nippon Claire Co., Ltd., Tokyo
- water (10 per group) water (10 per group)
- swimming was practiced in the running water pool (center flow rate 15.6 cm / sec) twice a day for a total of 20 minutes each. After 1 week of pre-breeding and swimming practice, they were allowed free intake of normal chow and water.
- an aqueous solution of a mixture of the above chicken extract powder 30 mg / ml + pork peptide 20 mg / ml + phosphatidylserine 10 mg / ml was orally administered once a day at a dose of lOml / kg for 7 days.
- the experimental animals were allowed to swim in the pool (center flow rate 23.6 cm / sec) until exhaustion, and the swimming endurance time was measured.
- the average elongation of Comparative Example 1 4 is assumed to be 1 0 0. Expressed as a relative value (%).
- Example 4 the same treatment was performed except that an aqueous solution of a mixture of chicken extract powder 30 mg / ml + pork peptide 20 mg / ml was administered as the aqueous solution.
- Example 4 the same treatment was performed except that an aqueous solution of a mixture of chicken extract powder 30 mg / ml + phosphatidylserine 10 mg / ml was administered as the aqueous solution.
- Example 4 the same treatment was performed except that an aqueous solution of a mixture of pork peptide 20 mg / inl + phosphatidylserine 10 mg / ml was administered as the aqueous solution.
- Example 4 the same treatment was performed except that an aqueous solution of chicken extract powder 30 mg / ml was administered as the aqueous solution.
- Example 4 the same treatment was performed except that an aqueous solution of 20 mg / ml of pork peptide was administered as the aqueous solution.
- Example 4 the same treatment was performed except that an aqueous solution of phosphatidylserine 10 mg / ml was administered as the aqueous solution.
- Example 4 the same treatment was performed except that only water was administered as an aqueous solution.
- the results of the above test are shown in Table 3 below.
- the growth rate (%) of swimming holding time is a relative value when the average value of Comparative Example 14 is 100.
- the mixture of chicken extract powder + pork peptide significantly increased endurance in the swimming test. Therefore, it was found that the antistress food of the present invention has a high endurance improving effect.
- a capsule was prepared by filling 250 mg of a mixture of chicken extract powder 4.5 mg, pork peptide 20 mg and phosphatidylserine lO mg in a conventional manner.
- Chenic acid 0.2 parts
- orange juice 3 5 parts
- sugar 5 parts
- chicken extract powder 30 mg / ral + pork peptide 20 mg / ml + phosphine 30 ml of an aqueous solution of a mixture of 10 mg / ml of vatidylserine was added, and after cooling, the container was filled and sterilized by heating at 85 ° C. for 30 minutes to produce a fruit juice drink.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/018344 WO2006059397A1 (ja) | 2004-12-02 | 2004-12-02 | 抗ストレス性食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/018344 WO2006059397A1 (ja) | 2004-12-02 | 2004-12-02 | 抗ストレス性食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006059397A1 true WO2006059397A1 (ja) | 2006-06-08 |
Family
ID=36564840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018344 WO2006059397A1 (ja) | 2004-12-02 | 2004-12-02 | 抗ストレス性食品 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006059397A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020125276A (ja) * | 2019-02-06 | 2020-08-20 | 静岡県公立大学法人 | 持久力向上剤 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717855A (ja) * | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
JPH0920660A (ja) * | 1995-07-04 | 1997-01-21 | Suntory Ltd | 抗ストレス組成物 |
JP2001069949A (ja) * | 1999-09-06 | 2001-03-21 | Nippon Meat Packers Inc | 豚肉分解物及びそれを含有する食品 |
JP2002051730A (ja) * | 2000-08-08 | 2002-02-19 | Nippon Meat Packers Inc | スポーツ用食品 |
JP2003169632A (ja) * | 2001-12-08 | 2003-06-17 | Sapuri:Kk | 米胚芽油、卵黄油及びホスファチジルセリン含有の健康食品 |
JP2004520845A (ja) * | 2001-03-26 | 2004-07-15 | ギヴエンテイス・ゲゼルシヤフト・ミット・ベシュレンクテル・ハフツング | 認知能力を高めるための食品 |
-
2004
- 2004-12-02 WO PCT/JP2004/018344 patent/WO2006059397A1/ja not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717855A (ja) * | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
JPH0920660A (ja) * | 1995-07-04 | 1997-01-21 | Suntory Ltd | 抗ストレス組成物 |
JP2001069949A (ja) * | 1999-09-06 | 2001-03-21 | Nippon Meat Packers Inc | 豚肉分解物及びそれを含有する食品 |
JP2002051730A (ja) * | 2000-08-08 | 2002-02-19 | Nippon Meat Packers Inc | スポーツ用食品 |
JP2004520845A (ja) * | 2001-03-26 | 2004-07-15 | ギヴエンテイス・ゲゼルシヤフト・ミット・ベシュレンクテル・ハフツング | 認知能力を高めるための食品 |
JP2003169632A (ja) * | 2001-12-08 | 2003-06-17 | Sapuri:Kk | 米胚芽油、卵黄油及びホスファチジルセリン含有の健康食品 |
Non-Patent Citations (3)
Title |
---|
HARADA RIE.: "Tori Muneniku Chushutsubutsu (Chiken Extract) no Mause Yuei jikyuryoku ni Taisuru Koka.", JOURNAL OF JAPANESE SOCIETY OF NUTRITION, AND FOOD SCIENCE., vol. 55, no. 2, 2002, pages 73 - 78, XP002998034 * |
SATO MIKAKO ET AL: "Shokunikuchu Carnosine Oyobi Anserine no Undo Noryoku Kojo Sayo.", NIPPON SHOKUNIKU KENKYUKAI SOKAI TEISHUTSU GIAN OYOBI TAIKAI KOEN YOSHI., vol. 43, 2002, pages 21 - 26, XP002998033 * |
SATO MIKAKO.: "Tori Muneniku Chushutsubutsu (CBEX) Choki Sesshu ga Kokkakukinchu Carnosine Nodo to Tanjikan kokyodo Undo Performance ni Oyobosu Eikyo.", JAPANESE JOURNAL OF PHYSICAL FITNESS AND SPORT MEDICINE., vol. 52, no. 3, 2003, pages 255 - 263, XP002998035 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020125276A (ja) * | 2019-02-06 | 2020-08-20 | 静岡県公立大学法人 | 持久力向上剤 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101390044B1 (ko) | 내장 지방 축적 억제제 및 혈중 아디포넥틴 농도 증가 촉진및/또는 감소 억제제 | |
KR101616586B1 (ko) | 간기능 보호제 | |
JP2004182630A (ja) | 持続性筋肉疲労改善剤 | |
TW200848064A (en) | Process for producing osteocalcin-containing extract | |
JPH07278012A (ja) | 新陳代謝促進剤およびそれを配合した食品 | |
EP2123666B1 (en) | Peptides from casein for use as agents in liver pathologies | |
JPH04183371A (ja) | 骨強化食品、飼料及び医薬 | |
KR101433648B1 (ko) | 피부미용제 | |
JP4808218B2 (ja) | 抗糖尿病作用を有する蛋白加水分解物 | |
JP2001002583A (ja) | 血糖値上昇抑制剤 | |
WO2006115153A1 (ja) | 肌状態改善作用を有する食品組成物 | |
JPH0453471A (ja) | 骨強化食品、飼料及び医薬 | |
JP3690820B2 (ja) | 乳児用栄養組成物 | |
US5897881A (en) | Hard tissue intactly dissolved materials and method for producing the same | |
EP3174548B1 (en) | Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose | |
JP5677937B2 (ja) | 自律神経活動調節用組成物および自律神経を調節する方法 | |
WO2006059397A1 (ja) | 抗ストレス性食品 | |
JPH07215851A (ja) | 抗アレルギー剤及びその製造法 | |
EP3749339B1 (en) | Marine protein hydrolysate with low fluoride and trimethylamin content | |
JPWO2009057282A1 (ja) | 骨吸収抑制用食品素材 | |
JPH0198445A (ja) | 経口摂食組成物 | |
JP5312780B2 (ja) | 血中アンモニア濃度を低下させる飲食物および医薬組成物 | |
JP2001340055A (ja) | 家畜、家禽類給餌方法および給餌用人工乳組成物 | |
JP5317456B2 (ja) | 内因性オピオイドペプチドの血中分泌促進用組成物 | |
JP3605528B2 (ja) | 体重増加抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 04822509 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |